Concepedia

Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines

Hugo You‐Hsien Lin, Kai‐Ting Chang, Chi‐Chih Hung, Chang‐Hung Kuo, Shang‐Jyh Hwang, Hung‐Chun Chen, Chih‐Hsing Hung, Sheng‐Fung Lin

BMC Immunology · 2014 · 64 citations · 28 references

DOIFull text

Open access

Abstract

Sirolimus downregulates the expression of chemokines in monocytes, including MCP-1, RANTES, IL-8, MIP-1α, and MIP-1β, by inhibiting the NF-κB-p65 and MAPK-p38 signalling pathways.

References

28

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

Markus Guba, Philipp von Breitenbuch, Markus Steinbauer et al. · Nature Medicine · 2002 · 1.7K citations

, , +9

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

John J. Bissler, Francis X. McCormack, Lisa R. Young et al. · New England Journal of Medicine · 2008 · 1.3K citations · Full text

The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response

Thomas Weichhart, Giuseppina Costantino, Marko Poglitsch et al. · Immunity · 2008 · 789 citations · Full text

, , +8

A human T cell-specific molecule is a member of a new gene family.

Thomas J. Schall, Jan Jongstra, B Dyer et al. · The Journal of Immunology · 1988 · 500 citations

Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents

Jean Fajadet, Marie-Claude Morice, Christoph Bode et al. · Circulation · 2005 · 214 citations · Full text